Pancreatic Ductal AdenocarcinomaSymptoms, Doctors, Treatments, Advances & More
Pancreatic Ductal Adenocarcinoma Overview
Learn About Pancreatic Ductal Adenocarcinoma
UT Southwestern Medical Center
Jason Fleming is a General Surgeon practicing medicine in Dallas, Texas. Dr. Fleming is rated as an Elite provider by MediFind in the treatment of Pancreatic Ductal Adenocarcinoma. He is also highly rated in 16 other conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Neuroendocrine Tumor, Pancreaticoduodenectomy, and Pancreatectomy.
Daniel Renouf practices practicing medicine in Vancouver, Canada. Mr. Renouf is rated as an Elite expert by MediFind in the treatment of Pancreatic Ductal Adenocarcinoma. He is also highly rated in 6 other conditions, according to our data. His clinical expertise encompasses Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Familial Pancreatic Cancer, Colorectal Cancer, and Pancreatectomy.
Samuel Oschin Cancer Center
Andrew Hendifar is a Hematologist practicing medicine in Los Angeles, California. Dr. Hendifar is rated as an Elite provider by MediFind in the treatment of Pancreatic Ductal Adenocarcinoma. He is also highly rated in 4 other conditions, according to our data. His clinical expertise encompasses Pancreatic Ductal Adenocarcinoma, Ampullary Cancer, Gastroesophageal Junction Cancer, Pancreaticoduodenectomy, and Pancreatectomy.
Summary: This early phase I trial aims to determine how cobimetinib, olaparib, onvansertib, azenosertib, AZD5305 or tremelimumab works in patients with pancreatic cancer. Validation of cobimetinib, olaparib, onvansertib azenosertib, AZD5305 and tremelimumab molecular targets will be explored by comparing pre-treatment biopsies with post-treatment specimens. This knowledge will help design future biomarker ...
Summary: This is a multi-center, non-randomized, single-arm, open-label, phase Ib, dose escalation/dose expansion study of PTM-101 when combined with neoadjuvant chemotherapy for the treatment of treatment-naïve subjects with borderline resectable and locally advanced pancreatic ductal adenocarcinoma (PDAC).
